Management

Charles J. Link Jr, MD, co-founded NewLink Genetics in 1999 with the idea of leveraging the body's immune system to fight cancer. He is chief executive officer, chief scientific officer, and chairman of the Board of Directors. Dr Link was appointed by United States Senator John Glenn of Ohio to the United States Air Force Academy where he studied chemistry. Prior to graduating, he was accepted to a special program at Stanford University School of Medicine in Stanford, California, where he received his bachelor's degree in chemistry and his medical degree. Dr Link interned at the University of California, San Francisco, and completed his residency and fellowship training in medical oncology at the National Cancer Institute in Bethesda, Maryland, where he also served as an attending physician. Dr Link practiced oncology for 18 years, most recently caring for patients part-time at Medical Oncology and Hematology Associates of Iowa from 1995 to 2013. He also served as director of the Human Gene Therapy Research Institute, which is part of the John Stoddard Cancer Center at Iowa Methodist Medical Center. In addition to spending time with his family, Dr Link enjoys exercising and pouring over scientific journals.

Nicholas Vahanian, MD, is one of the co-founders of NewLink Genetics. He has served as president and chief medical officer of the company since 2009 and previously served as chief operations officer. His current responsibilities include medical affairs, clinical affairs, regulatory affairs, manufacturing, and human resources. He has extensive experience in clinical trial design and drug development and has led the algenpantucel-L development program, including the IMPRESS trial, the largest trial ever conducted in the United States studying adjuvant therapy for patients with resected pancreatic cancer. Dr Vahanian began his research career at the National Cancer Institute and subsequently worked at the National Center for Human Genome Research Institute, both at the National Institutes of Health. He worked under the tutelage of Dr Michael Blaese, a pioneer in the field of human gene therapy. Dr Vahanian holds a BS in biology from Virginia Commonwealth University in Richmond, Virginia and an MBA from the University of Notre Dame in Notre Dame, Indiana. He attended St. Bartholomew’s and Royal London Hospital Medical College and earned his medical degree and subsequently completed a Molecular Oncology Fellowship at the John Stoddard Cancer Research Institute.

John Henneman joined NewLink Genetics in 2014 as executive vice president and chief financial officer. With more than 20 years of combined financial and operational management experience in the life sciences industry, John has been involved in nearly every part of the business, and is mainly responsible for finance, legal issues, and company administration. Prior to joining NewLink, John worked at Integra LifeSciences as general counsel, chief administrative officer, and chief financial officer, where he raised almost $1 billion in new capital from banks and debt and equity capital markets. He earned an AB in politics from Princeton University in Princeton, New Jersey, and a law degree from University of Michigan Law School in Ann Arbor, Michigan.

Recent Stock Transactions by John B. Henneman III
Date Type Shares Traded Price Range
Jan 4, 2017 Disposition (Non Open Market) 1,323 11.04
Jan 3, 2017 Disposition (Non Open Market) 164 10.28
Oct 1, 2016 Disposition (Non Open Market) 2,789 15.02
Jan 5, 2016 Sell 175 35.74
Jan 4, 2016 Acquisition (Non Open Market) 16,201 n/a
Oct 1, 2015 Disposition (Non Open Market) 4,199 35.32
May 14, 2015 Buy 3,000 37.30
Feb 18, 2015 Disposition (Non Open Market) 300 n/a
Jan 2, 2015 Acquisition (Non Open Market) 2,000 n/a
Nov 25, 2014 Buy 5,000 34.35
Oct 1, 2014 Acquisition (Non Open Market) 40,789 n/a

Eugene P. Kennedy, MD, FACS, is vice president for clinical and medical affairs at NewLink Genetics, where he leads clinical development across all immuno-oncology product candidates as well as investigator initiated trials. Prior to joining NewLink Genetics, he was on faculty and clinical staff at Thomas Jefferson University in Philadelphia, Pennsylvania where he served as associate professor of Surgery and held leadership positions as chief of the Section of Pancreaticobiliary Surgery and co-director of the Jefferson Pancreas, Biliary, and Related Cancers Center. Previously, Dr Kennedy held faculty positions at Johns Hopkins Hospital in Baltimore, Maryland, and the Louisiana State University School of Medicine in New Orleans, Louisiana. He has considerable experience in clinical trial design and implementation, leading both investigator initiated and industry sponsored efforts.

Carl Langren has served as NewLink Genetics’ vice president of finance since 2011. Previously, he was chief financial officer of BioProtection Systems, Housby Mixer Group, and Equity Dynamics, Inc. He served as a principal in Capital Management Solutions, president of Iowa Machinery and Supply, treasurer of DFM Corporation, and tax manager with McGladrey Pullen and Company. Carl received a BA in accounting from the University of Iowa in Iowa City, Iowa.

Recent Stock Transactions by Carl Langren
Date Type Shares Traded Price Range
Jan 4, 2017 Disposition (Non Open Market) 257 11.04
Jan 3, 2017 Disposition (Non Open Market) 883 10.28
Dec 14, 2016 Sell 3,943 10.85
Jan 5, 2016 Sell 1,095 34.60 - 35.42
Jan 4, 2016 Acquisition (Non Open Market) 3,142 n/a
Mar 18, 2015 Sell 16,358 53.00
Jan 2, 2015 Disposition (Non Open Market) 551 43.65
Jan 2, 2015 Acquisition (Non Open Market) 5,100 n/a
Oct 11, 2014 Disposition (Non Open Market) 56,691 18.96
Oct 11, 2014 Acquisition (Non Open Market) 56,691 18.96
Jan 21, 2014 Sell 7,173 34.81
Jan 15, 2014 Sell 2,827 29.95
Jan 8, 2014 Disposition (Non Open Market) 2,400 n/a
Jan 8, 2014 Acquisition (Non Open Market) 1,200 n/a
Jan 2, 2014 Acquisition (Non Open Market) 5,700 n/a
Nov 7, 2013 Statement of Ownership 0 n/a
Nov 7, 2013 Statement of Ownership 0 n/a

Mario Mautino, PhD, is senior vice president of drug discovery and the company’s intellectual property officer. Dr Mautino joined NewLink as a senior scientist in 2001, participating in preclinical research related to HyperAcute® vaccines. Since 2007 he has been leading NewLink’s small molecule drug discovery program targeting the IDO and TDO pathways, contributing to advancing indoximod and GDC-0919 to clinical development. Dr Mautino received his licentiate in biological chemistry in 1990 and his PhD in molecular genetics in 1995 from the National University of Córdoba in Córdoba, Argentina, where he also conducted 2 years of postdoctoral research in molecular epigenetics. He trained from 1997 to 2001 as a postdoctoral fellow in human gene therapy and HIV virology at the Clinical Gene Therapy Branch, National Institutes of Health. He enjoys hiking and nature photography.

Thomas Monath, MD, Chief Scientific Officer and Chief Operations Officer of the Infectious Disease Division, joined NewLink Genetics in 2014. Dr Monath brings 24 years of pharmaceutical experience to the team including 14 years as chief scientific officer and executive director at Acambis, Inc., where he pioneered numerous vaccines including those to combat dengue, West Nile, and yellow fever. Dr Monath has also served as adjunct professor at Harvard School of Public Health.

Prior to his pharmaceutical work, Dr Monath served 24 years in the US Army in the uniformed services (Army and US Public Health Service). He was Director, Division of Vector-Borne Viral Disease, Centers for Disease Control (CDC), and Chief, Virology Division, US Army Medical Research Institute of Infectious Disease (USAMRIID). Dr Monath’s role at NewLink will be to lead the company’s effort to develop and deliver the Ebola and other infectious disease vaccines. He has published 425 papers and 6 books about vaccine development and the epidemiology, immunology, and pathogenesis of arboviruses.

Dr Monath received both his undergraduate and MD from Harvard and trained in internal medicine at Peter Bent Brigham Hospital.

Gary Potter is vice president of manufacturing and supply chain, and he is responsible for the manufacturing processes for NewLink Genetics’ HyperAcute® products. He has more than 30 years of experience in clinical and commercial manufacturing of biologics, startup, and commissioning of manufacturing facilities; cell culture process development; and international tech transfer (Austria, Canada, and Switzerland). Prior to joining NewLink Genetics, Gary held leadership positions in manufacturing at Cell Genesys Inc., Abgenix Inc., Baxter Bioscience, and Creative Biomolecules. At Abgenix and Baxter Bioscience, he successfully led the cell culture functional areas through regulatory inspections. He received a BA in biology from Hamline University in St Paul, Minnesota. He is a dedicated outdoorsman, who is keen on adventures. He also is an avid motorcyclist.

Gabriela R. Rossi, PhD, vice president of biologics development, joined NewLink Genetics in 2003. Prior to her appointment as vice president, Dr Rossi held positions as director of the Tumor Immunology Department and as a senior scientist. Dr Rossi received her PhD in immunology at the National University of Córdoba in Córdoba, Argentina. She continued postdoctoral training at the Holland Laboratories American Red Cross in Maryland, and her postdoctoral work at the National Institutes of Health Clinical Gene Therapy Branch and the National Cancer Institute Surgery Branch in Bethesda, Maryland. She has extensive experience within the HyperAcute® platform. Dr Rossi has 2 children. One of her favorite things to do is long distance running; she has finished 14 marathons and one 50K.

Eugene Sackett is vice president of human resources at NewLink Genetics. He has more than 25 years of experience in human resources in the pharmaceutical and technology industries. Eugene is responsible for the development of all human resource strategies, processes, and HR metrics that support the achievement of the organization's business goals.

Prior to joining NewLink Genetics, Eugene held management positions at Iroko Pharmaceuticals, Cephalon/Teva Pharmaceuticals, Wyeth/Pfizer Pharmaceuticals, and Unisys. He has held diverse leadership roles as a human resources business partner and in HR centers of excellence in talent acquisition, employee relations, and employee benefits. He played key roles in numerous commercial build-outs and reorganizations including building the first commercial organization at Iroko Pharmaceuticals in 2013. 

Eugene earned a BS in finance from Ithaca College in Ithaca, New York. He is an avid golfer, self-taught chef, and enjoys spending time at home with his family.

Brian Wiley is chief commercial officer at NewLink Genetics. He has more than 20 years of experience in pharmaceutical commercialization and business development. Brian is responsible for commercialization strategy and business development initiatives for all portfolio products. Prior to joining NewLink Genetics, Brian held management positions at Celgene Corporation, Gloucester Pharmaceuticals, Millennium/Takeda Pharmaceuticals, and Aventis/Sanofi Pharmaceuticals. He played key roles in numerous oncology product launches, the sale of Gloucester Pharmaceuticals to Celgene in 2009, and the acquisition of Abraxis Health by Celgene in 2010. He earned a BA in marketing from Pennsylvania State University in University Park, Pennsylvania.

Recent Stock Transactions by Brian Wiley
Date Type Shares Traded Price Range
Jan 4, 2017 Disposition (Non Open Market) 603 11.04
Jan 3, 2017 Disposition (Non Open Market) 1,237 10.28
Jan 5, 2016 Sell 1,295 34.26 - 35.20
Jan 4, 2016 Acquisition (Non Open Market) 6,382 n/a
Mar 2, 2015 Automatic Sell 20,000 44.03 - 46.24
Mar 2, 2015 Option Execute 20,000 11.79
Feb 17, 2015 Automatic Sell 10,000 40.07
Feb 17, 2015 Option Execute 10,000 11.79
Jan 2, 2015 Disposition (Non Open Market) 540 43.65
Jan 2, 2015 Acquisition (Non Open Market) 7,400 n/a
Jan 2, 2015 Automatic Sell 20,000 39.68 - 40.98
Jan 2, 2015 Option Execute 20,000 11.79
Feb 3, 2014 Automatic Sell 20,000 36.41
Feb 3, 2014 Option Execute 20,000 11.79
Jan 22, 2014 Automatic Sell 5,000 35.64
Jan 22, 2014 Option Execute 5,000 11.79
Jan 21, 2014 Automatic Sell 10,000 35.01
Jan 21, 2014 Option Execute 10,000 11.79
Jan 15, 2014 Automatic Sell 10,000 30.00
Jan 15, 2014 Option Execute 10,000 11.79
Jan 13, 2014 Automatic Sell 10,000 25.18
Jan 13, 2014 Option Execute 10,000 11.79
Jan 2, 2014 Acquisition (Non Open Market) 5,700 n/a
Jan 2, 2013 Statement of Ownership 0 n/a

Jun Zhao, PhD, joined NewLink Genetics in 2015 as vice president of quality and compliance. Dr Zhao has more than 15 years of pharmaceutical experience in the areas of quality, regulatory CMC, CMO management, research and development, and supply operations, including small molecules and biologics. Prior to NewLink, he held various leadership positions at Eisai Inc.’s global quality organizations. He led teams to successfully host regulatory inspections, support regulatory dossier preparation, product launch, and commercial supply for global markets. Prior to Eisai, Dr Zhao served in P&G Pharma’s product development unit, leading and participating in various CMC teams to support clinical and commercial products. Dr Zhao earned his PhD in chemistry at the Ohio State University in Columbus, Ohio. He enjoys reading, sports, and traveling with his family.

Stock transaction information provided by EDGAR Online. NewLink Genetics Corporation makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating, or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.